STOCK TITAN

Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cabaletta Bio, a clinical-stage biotechnology firm listed on Nasdaq as CABA, announced that its CEO, Steven Nichtberger, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. A live webcast of the event will be available on the company's website and a recording will be accessible for 90 days post-event. Cabaletta is focused on engineered T cell therapies for B cell-mediated autoimmune diseases with its lead candidate, DSG3-CAART, currently in clinical trials.

Positive
  • None.
Negative
  • None.

PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m. ET.

A live webcast of the presentation will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

 


FAQ

What is the date and time of the presentation by Cabaletta Bio at the JP Morgan Healthcare Conference?

Cabaletta Bio will present on January 14, 2021, at 5:20 p.m. ET.

Where can I watch the live webcast of Cabaletta Bio's presentation?

The live webcast can be viewed on the News and Events section of Cabaletta Bio's website.

What is the focus of Cabaletta Bio's research and development?

Cabaletta Bio focuses on engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

What is the lead product candidate of Cabaletta Bio?

The lead product candidate is DSG3-CAART, being evaluated for mucosal pemphigus vulgaris.

Has the FDA granted any designations to Cabaletta Bio's products?

Yes, DSG3-CAART received Fast Track Designation from the FDA in May 2020.

Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

CABA Latest News

CABA Stock Data

214.45M
48.85M
3.1%
107.69%
18.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PHILADELPHIA